\
&
Contact us
\
&
Contact us
Published on | 2 years ago
ProgrammesThe Commission has published the ex-post evaluation of Horizon 2020 (41% of projects are still running). The Commission has assessed a.o. the scientific, societal and economic impact of the programme with domain-specific details; the performance of the simplificaiton measures; and the Horizon 2020 leverage towards additional R&I resources. The Commission calculated that the overall success rate was on average 12%. They estimated that over 276000 peer-reviewed publications are produced, of which 3.9% are in the top 1% most cited publications worldwide. They aknowledged that there are not enough monitoring arrangements to capture wider societal impact - efforts to improve under Horizon Europe are on-going.
Interesting links:
- Commission report (12 pages)
- Exectuve summary (4 pages)
- Evaluation report (staff working document)(100 pages)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
